130 related articles for article (PubMed ID: 15961782)
1. Cognitive impairment, aromatase inhibitors, and age.
Tralongo P; Di Mari A; Ferrau' F
J Clin Oncol; 2005 Jun; 23(18):4243. PubMed ID: 15961782
[No Abstract] [Full Text] [Related]
2. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Benson JR
J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
[No Abstract] [Full Text] [Related]
3. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?
Mackey JR
J Clin Oncol; 2011 Apr; 29(12):1504-6. PubMed ID: 21422423
[No Abstract] [Full Text] [Related]
4. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
5. [For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].
Jonat W
MMW Fortschr Med; 2006 Mar; 148(12):10. PubMed ID: 16625996
[No Abstract] [Full Text] [Related]
6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
7. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
8. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
Altundag K; Bulut N; Sari E; Harputluoglu H
Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
[No Abstract] [Full Text] [Related]
9. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors and mental function.
Tralongo P; Dimari A; Repetto L
J Am Geriatr Soc; 2005 Jan; 53(1):166. PubMed ID: 15667399
[No Abstract] [Full Text] [Related]
11. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
12. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
13. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
15. Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Tuma RS
J Natl Cancer Inst; 2006 Jan; 98(2):86-7. PubMed ID: 16418506
[No Abstract] [Full Text] [Related]
16. Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors.
Batalo M; Nagaiah G; Abraham J
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1277-82. PubMed ID: 21916581
[TBL] [Abstract][Full Text] [Related]
17. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD
Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
[TBL] [Abstract][Full Text] [Related]
18. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
19. Managing patients on endocrine therapy: focus on quality-of-life issues.
Whelan TJ; Pritchard KI
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1056s-1060s. PubMed ID: 16467124
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors for adjuvant treatment of postmenopausal breast cancer.
Med Lett Drugs Ther; 2011 Jun; 53(1366):47-8. PubMed ID: 21659970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
